Cumberland Pharmaceuticals (NASDAQ:CPIX - Get Free Report) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating in a research note issued to investors on Thursday.
Cumberland Pharmaceuticals Stock Performance
NASDAQ:CPIX traded down $1.38 during trading hours on Thursday, reaching $4.99. 205,058 shares of the stock were exchanged, compared to its average volume of 857,918. The firm has a 50 day simple moving average of $3.82 and a 200-day simple moving average of $2.27. The company has a quick ratio of 0.99, a current ratio of 1.13 and a debt-to-equity ratio of 0.41. Cumberland Pharmaceuticals has a 52 week low of $1.04 and a 52 week high of $7.25. The stock has a market capitalization of $70.07 million, a P/E ratio of -6.48 and a beta of -0.18.
Cumberland Pharmaceuticals (NASDAQ:CPIX - Get Free Report) last announced its earnings results on Tuesday, March 4th. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter. Cumberland Pharmaceuticals had a negative net margin of 29.54% and a negative return on equity of 9.50%. The company had revenue of $10.44 million during the quarter.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Cumberland Pharmaceuticals stock. Two Sigma Investments LP boosted its position in shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX - Free Report) by 94.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 37,649 shares of the specialty pharmaceutical company's stock after purchasing an additional 18,271 shares during the period. Two Sigma Investments LP owned about 0.27% of Cumberland Pharmaceuticals worth $89,000 at the end of the most recent quarter. Institutional investors and hedge funds own 15.51% of the company's stock.
About Cumberland Pharmaceuticals
(
Get Free Report)
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
See Also
Before you consider Cumberland Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cumberland Pharmaceuticals wasn't on the list.
While Cumberland Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
